The Atlanta Center for Microsystems-Engineered Point-of-Care Technologies (ACME POCT) is a nationally renowned academic partnership between Emory University, Georgia Tech, and Children’s Healthcare of Atlanta. We were founded in 2018 as part of the National Institutes of Health Point-of-Care Technology Research Network (POCTRN).
Our mission is to foster collaboration among clinicians, technologists, and entrepreneurs to accelerate innovation and translation of microsystems-engineered technologies including microchip-enabled devices such as microelectromechanical systems (MEMs)-based sensors, microfluidics, and smartphone-based systems.
Announcing the ACME POCT 2024-25 Call for Proposals
Do you have a promising point-of-care medical technology in need of further development? ACME POCT is offering a wide variety of engineering, regulatory, clinical, analytical, human factors/usability or other specific expertise to project teams currently developing microsystems-based POC technologies. LEARN MORE: Expression of Interest due 11:59 pm EDT March 31st, 2024
Register for GLUE to Learn About Our Call & Services (2pm EST 2/27/24)
The Oliver Brand Memorial Lecture Series presents "ACME POCT Services Accelerate Translation to Clinical Impact: How To Win a Year of Development Support for Your Microsystems Technology" Attend this talk to learn more about the services offered by the ACME POCT to assess how they match your project needs, and to ask your questions about our current solicitation and application process. Register here to attend this GLUE event.
In Metro-Atlanta? Sign Up to Get a COVID-19/Flu/RSV Test With Us
Learn how and where you can get tested for COVID-19/flu/RSV and contribute to research at the same time!
Rapid Acceleration of Diagnostics (RADxsm) Program for COVID-19
The overall goal of ACME POCT is to assist and enable inventors from across the country who have developed microsystems-based POC technologies for applications that are beyond proof-of-concept to define their specific clinical needs, conduct clinical validation, and refine their technology, with the objective of accelerating the path to translation and clinical adoption and directly addressing the barriers thereof.